Eagle Bancorp 10-Q: Q3 EPS $0.79, But Nonperforming Loans Jump to 2.53% of Portfolio
EGBN has more than doubled off its 52-week low of $15.58.
Summary
Eagle Bancorp's Q3 10-Q confirms the $24.2 million ($0.79 per share) profit already reported October 21, but shows nonperforming loans up to $166.0 million (2.53% of loans) with allowance coverage down to 73% from 149% at year-end.
Key Events · Earnings and Guidance · EGBN
-
Q3 Profit Confirmed at $24.2 Million
Net income of $24.2 million, or $0.79 per diluted share, versus a $67.5 million loss in Q3 2025; the provision for credit losses fell to $2.8 million from $113.2 million.
-
Nonperforming Loans Jump to $166.0 Million
Nonperforming assets rose to $166.0 million (1.75% of total assets) from $109.0 million at December 31, 2025; nonperforming loans are 2.53% of total loans versus 1.47%.
-
Allowance Coverage Falls to 73%
The $120.8 million allowance for credit losses covers 73% of nonperforming loans, down from 149% at year-end; net charge-offs were $78.0 million, or 1.53% of average loans annualized, in the first nine months.
-
Balance Sheet Shrinks; Brokered Deposits Cut
Loans held for investment fell $717.1 million (9.8%) to $6.6 billion and deposits fell $1.1 billion, with brokered deposits down to $851.5 million (11% of deposits) from $3.3 billion (36%).
Analysis · EGBN · Finance
The headline numbers were already out on October 21 — $24.2 million of Q3 net income, or $0.79 per diluted share, versus a $67.5 million loss a year earlier — and the swing is almost entirely a credit story: the quarterly provision fell to $2.8 million from $113.2 million. What the 10-Q adds is the balance-sheet damage behind that clean quarter. Nonperforming assets climbed to $166.0 million, or 1.75% of total assets, from $109.0 million at year-end, and the allowance now covers only 73% of nonperforming loans versus 149% at December 31. Management is shrinking its way out of the problem: loans held for investment are down $717.1 million (9.8%) and deposits down $1.1 billion as brokered funding was cut to $851.5 million from $3.3 billion. Capital is the offset — CET1 at 14.99% and total risk-based capital at 16.25%, both well above requirements — and the CRE concentration finally dropped under the 300% regulatory guideline at 245.8% of total capital. The tension for holders is that earnings quality depends on how much more of the $166.0 million nonperforming book has to be written down; the thin 73% coverage leaves little cushion if collateral values slip further.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EGBN was trading at $33.21 on NASDAQ in the Finance sector, with a market capitalization of approximately $1B. The 52-week trading range was $15.58 to $35.05. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.